Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
11.71
-0.15 (-1.26%)
At close: Apr 24, 2024, 4:00 PM
11.92
+0.21 (1.79%)
After-hours: Apr 24, 2024, 7:52 PM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for IOVA stock have an average target of 25.64, with a low estimate of 19 and a high estimate of 34. The average target predicts an increase of 118.96% from the current stock price of 11.71.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for IOVA stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 2 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 13 | 13 | 13 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $18 → $19 | Buy | Maintains | $18 → $19 | +62.25% | Mar 14, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $17 → $26 | Strong Buy | Maintains | $17 → $26 | +122.03% | Mar 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +173.27% | Mar 4, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $25 | Buy | Maintains | $22 → $25 | +113.49% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +173.27% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
165.51M
from 1.19M
Increased by 13,820.10%
Revenue Next Year
427.00M
from 165.51M
Increased by 157.99%
EPS This Year
-1.31
from -1.89
EPS Next Year
-0.73
from -1.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 291.4M | 781.4M | 1.4B | 1.7B | 1.7B |
| Avg | 165.5M | 427.0M | 665.9M | 1.2B | 1.1B |
| Low | 32.5M | 127.9M | 118.6M | 455.7M | 637.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24,406.3% | 372.1% | 233.0% | 149.4% | 36.4% |
| Avg | 13,820.1% | 158.0% | 56.0% | 82.1% | -6.4% |
| Low | 2,636.4% | -22.7% | -72.2% | -31.6% | -47.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.49 | 0.36 | 1.87 | 1.40 |
| Avg | -1.31 | -0.73 | - | 1.14 |
| Low | -1.76 | -1.55 | -1.19 | 0.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.